

Regd Off: **Camlin Ltd.**, Camlin House, J. B. Nagar, Andheri (E), Mumbai 400 059.

(RS. IN LACS)

SR. NO.	PARTICULARS	QUARTER ENDED 30.06.2005 (UNAUDITED)	QUARTER ENDED 30.06.2004 (UNAUDITED)	PREVIOUS ACCOUNTING YEAR ENDED 31.03.2005 (AUDITED)
1.	GROSS SALES LESS: TRADE DISCOUNT LESS: EXCISE DUTY	5,723.99 21.27 202.21	6,113.94 69.78 236.81	20,843.72 363.13 716.26
	NET SALES	5,500.51	5,807.35	19,764.33
2.	OTHER INCOME	24.56	60.25	175.19
3.	TOTAL INCOME (1+2)	5,525.07	5,867.60	19,939.52
4.	TOTAL EXPENDITURE (A) (INCREASE)/DECREASE IN STOCK (B) CONSUMPTION OF RAW MATERIALS (C) PERSONNEL COST (D) OTHER EXPENDITURE	300.58 3,381.96 445.31 902.18	154.75 3,453.82 580.49 1,203.91	255.06 12,022.00 2,388.61 5,075.31
	TOTAL	5,030.03	5,392.97	19,740.98
5.	INTEREST	128.16	97.67	454.92
6.	DEPRECIATION	131.01	111.08	456.23
7.	V R S COMPENSATION	38.10	-	19.05
8.	PROFIT/(LOSS) BEFORE TAXATION (3-4-5-6-7)	197.77	265.88	(731.66)
9.	PROVISION FOR TAXATION - CURRENT YEAR - PRIOR YEARS	81.38 -	100.60 -	(260.14) 16.98
10.	NET PROFIT/(LOSS) (8-9)	116.39	165.28	(488.50)
11.	PAID UP EQUITY SHARE CAPITAL (FACE VALUE OF RS.10/- PER SHARE)	480.00	480.00	480.00
12.	RESERVES EXCLUDING REVALUATION RESERVE (AS PER BALANCE SHEET)	-	-	967.81
13.	EARNING PER SHARE - BASIC AND DILUTED (Rs.)	2.42	3.44	(10.18)
14.	AGGREGATE OF NON-PROMOTER SHARE HOLDING - NUMBER OF SHARES - PERCENTAGE OF SHARE HOLDING	2477326 51.61	2476526 51.59	2477326 51.61

**Notes:**

- Company's sales and expenses in the current quarter are lower due to
  - Company substantially restricting operations of pharmaceutical division.
  - Company having successfully implemented VRS on April 02, 2005 and shifted its manufacturing activities at Andheri to other manufacturing units of the company.
- Provisions for Taxation includes Current Tax, Deferred Tax and Fringe Benefit Tax.
- Previous period figures have been reclassified in conformity with the classifications of the current period results.
- There were no investor complaints pending at the beginning of the current quarter. During the quarter, the Company received 1 investor complaint, which was resolved during the quarter.
- These results have been reviewed by Audit Committee and taken on record at the meeting of Board of Directors held on July 30, 2005.

**QUARTERLY REPORTING OF SEGMENTWISE REVENUE, RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE 41 OF THE LISTING AGREEMENT**

(RS. IN LACS)

SR. NO.	PARTICULARS	QUARTER ENDED 30.06.2005 (UNAUDITED)	QUARTER ENDED 30.06.2004 (UNAUDITED)	PREVIOUS ACCOUNTING YEAR ENDED 31.03.2005 (AUDITED)
1.	SEGMENT REVENUE (NET OF TRADE DISCOUNT & EXCISE) / INCOME FROM OPERATIONS a) CONSUMER PRODUCTS b) PHARMACEUTICALS (DISCONTINUING OPERATIONS) c) FINE CHEMICALS TOTAL LESS: INTER SEGMENT REVENUE	4,598.55 42.35 862.07 5,502.97 -	4,297.54 449.90 1,095.69 5,843.13 -	13,727.46 2,407.94 3,717.78 19,853.18 -
	NET SALES/INCOME FROM OPERATIONS	5,502.97	5,843.13	19,853.18
2.	SEGMENT RESULTS {PROFIT/(LOSS) BEFORE TAX & INTEREST FROM EACH SEGMENT} a) CONSUMER PRODUCTS b) PHARMACEUTICALS (DISCONTINUING OPERATIONS) c) FINE CHEMICALS TOTAL LESS: i) INTEREST ii) OTHER UNALLOCABLE EXPENDITURE NET OFF UNALLOCABLE INCOME TOTAL PROFIT/(LOSS) BEFORE TAX	523.19 (118.43) 112.82 517.58 128.16 191.65 197.77	500.02 (137.24) 290.27 653.05 97.67 289.50 265.88	597.86 (538.11) 711.29 771.04 454.92 1,047.78 (731.66)
3.	CAPITAL EMPLOYED (SEGMENT ASSETS - SEGMENT LIABILITIES) a) CONSUMER PRODUCTS b) PHARMACEUTICALS (DISCONTINUING OPERATIONS) c) FINE CHEMICALS TOTAL	3,856.45 464.69 3,542.16 7,863.30	4,111.10 914.23 2,468.32 7,493.65	3,301.55 660.03 2,775.18 6,736.76

**For Camlin Limited**

 Place : Mumbai  
Date : July 30th, 2005.

**Dilip Dandekar**  
Chairman & Managing Director